Login to Your Account



Financings Roundup

While Others Stall on Obesity, Zafgen Accelerates with $33M

By Catherine Shaffer


Thursday, July 7, 2011
Tom Hughes, President and CEO of Zafgen Inc., is not concerned about the FDA's upcoming general advisory committee in 2012 to address requirements for cardiovascular assessments for obesity therapeutics. Whereas the announcement has left late-stage obesity companies like Orexigen Therapeutics Inc., Vivus Inc. and Arena Pharmaceuticals Inc. in a sort of limbo, Cambridge, Mass.-based Zafgen is moving forward with confidence.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription